TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed study CLDT600ACN04 study and will be available to immediately rollover into this study without discontinuation of study drug.~* Patient was not discontinued from the previous CLDT600ACN04 study.~* Adult patients with CHB (HBeAg positive or HBeAg negative).~* HBV DNA PCR undetectable in recent 12 months.~Exclusion Criteria:~* Pregnant or breastfeeding, or has plan of pregnant during study period.~* Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV at screening visit.~* Patient has received within the past 12 months any anti-HBV treatment combination (add-on therapy) or switch to other anti HBV treatment from Telbivudine at investigator's discretion.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients are included in the study if they meet all the following criteria:~* Exclusively breastfed healthy infants of both sexes, aged ≤ 7 weeks.~* Diagnosis of IC according to Rome III criteria.~* Written informed consent of the parent/tutor.~Exclusion Criteria:~Patients are excluded from this study if they meet any of the following criteria:~* Birth weight \< 2500 g.~* Gestational age \< 37 weeks.~* APGAR 5 minutes \< 7.~* Formula feeding.~* Stunting/loss of weight (\< 100 g/weeks from birth to the last reported weight).~* Neurological diseases.~* Known or suspected food allergy.~* Gastroesophageal reflux disease.~* Use of substances that alter gut microbiota (probiotics, prebiotics, antibiotics, gastric acidity inhibitors) in the last 2 weeks prior the enrollment.~* History of fever and/or infectious diseases in the last 2 weeks prior to enrollment.~* Ongoing systemic infections.~* History of congenital infections.~* Chronic intestinal diseases (cystic fibrosis or other forms of primitive pancreatic insufficiency)~* Primitive or secondary malformations of the gastrointestinal tract (such as esophageal atresia, intestinal atresia, short bowel syndrome, malrotation).~* Metabolic diseases.~* Genetic diseases and chromosomal abnormalities.~* Primary or secondary immunodeficiencies.~* Not sufficient reliability or presence of conditions that may result in non-compliance/adherence of the patient to the Protocol.~* Previous participation in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Weeks
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
- Group II (Type: PLACEBO_COMPARATOR): patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients who need high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） therapy.~* 2. Patients who continued treatment for MMN without addition or increase at 30 days before informed consent.~* 3. Patients who MRC score increased 1 stage in greater than or equal to 2 muscles and not decreased relative other muscles to before at after in high-dose intravenous immunoglobulin therapy.~* 4. Patients with greater than or equal to twenty years old at informed consent.~Exclusion Criteria:~* 1. Patients treated with Plasmapheresis at 3 months before informed consent.~* 2. Patients treated with Rituximab or Natalizumab at 6 months before informed consent.~* 3. Patients treated with Interferon-beta at 6 months before informed consent.~* 4. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.~* 5. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.~* 6. Patients with history of shock or hypersensitivity for NPB-01.~* 7. Patients with IgA deficiency.~* 8. Patients with malignancy.~* 9. Patients with impaired liver function.~* 10. Patients with impaired renal function.~* 11. Patients with cerebro- or cardiovascular disorders.~* 12. Patients with high risk of thromboembolism.~* 13. Patients with hemolytic/hemorrhagic anemia.~* 14. Patients with decreased cardiac function.~* 15. Patients with decreased platelet.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- NPB-01 (Type: EXPERIMENTAL): Intravenous immunoglobulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PD.~* Patients with a Modified Hoehn and Yahr stage \<3.~Exclusion Criteria:~* Patients with a clinically significant or unstable medical or surgical condition that would preclude his/her safe and complete study participation.~* Patients with a clinically significant or unstable vascular disease.~* Patients with a clinically significant psychiatric illness, including a major depression, which compromises their ability to provide consent or participate fully in the study.~* Patients with a Mini Mental State Examination (MMSE) score ≤24.~* Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious lesion.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rasagiline (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Singing Your Negative Body-Related Thoughts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Restrained eaters, as indicated by a score of 15 or greater on the Revised Restraint Scale (Polivy, Herman, \& Howard, 1988)~* Identify as female~* Age 17 and older~Exclusion Criteria:~* Under age 17~* Do not identify as female~* Scores below 15 on the Revised Restraint Scale (Polivy, Herman, \& Howard, 1988).

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Verbally repeat body-related thoughts (Type: EXPERIMENTAL): A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
- Sing negative body-related thoughts (Type: EXPERIMENTAL): A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
- Verbally repeat body-unrelated thoughts (Type: NO_INTERVENTION): A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds.
- Sing body-unrelated thoughts (Type: NO_INTERVENTION): A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Mouth Film for Craving Relief.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI within the range of 19-35 kg/m2;~* Current cigarette smokers who have smoked regularly daily for at least a year,~* Participants who smoke their first cigarette more than 30 minutes after waking up~Exclusion Criteria:~* Known or suspected intolerance or hypersensitivity to nicotine (or closely related compounds) or any of the stated ingredients in formulation.~* Any participant whose CO level rises during the sequestration period (i.e., the subject's two expired CO assessments immediately prior to the provoked craving paradigm are higher than the mean baseline CO assessment) and, in the opinion of the investigator, may have smoked during that time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nicotine Mouth Film (Type: EXPERIMENTAL): mint nicotine mouth film, buccal administration
- Nicotine Lozenge (Type: ACTIVE_COMPARATOR): nicotine lozenge, buccal administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma~  * Relapsed following chemotherapy and eligible for platinum-containing regimen~* Measurable disease~  * Must be at least 1.5 x 1.5 cm~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 75,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~Renal:~* Creatinine no greater than 1.5 times upper limit of normal~Cardiovascular:~* No uncontrolled hypertension~Other:~* HIV negative~* No other active malignancy~* No uncontrolled diabetes mellitus~* No uncontrolled peptic ulcer disease~* No uncontrolled infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rituximab+dexamethasone+cisplatin+cytarabine+sargramostim (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least18 years and pre-menopausal;~* scheduled to undergo elective breast cancer operation;~* American Society of Anaesthesiologists (ASA) risk classification I-II.~Exclusion Criteria:~* (1) patient refusal; (2) known hypersensitivity to the study medication (ropivacaine); (3) long-term use of opioids; (4) a history of psychiatric or neurological disease; (5) a preoperative Pittsburgh Sleep Quality Index (PSQI) global score higher than 6.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: SHAM_COMPARATOR): All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
- stellate-ganglion block (Type: EXPERIMENTAL): All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Planned anesthesia with use of LMA (laryngeal mask airway)~* Planned duration of anesthesia between 0.5 and 2 hours~* Age between 18-75 years~* Both gender~* Body mass index (BMI) \<35~* ASA 1-3~* Written informed consent prior to study participation~Exclusion Criteria:~* Planned additional regional and local anesthesia~* Contra-indication for the use of a laryngeal mask airway~* Asthma~* COPD IV~* Known allergy or hypersensitivity to any drugs administered during this study~* Women who are pregnant, breast-feeding or women of childbearing potential not using adequate contraceptive methods~* Participation in a drug or device trial within the previous 30 days.~* Patients legally unable to give written informed consent.~* Patients with severe psychiatric disorders~* Recent (\<6 months) history of alcohol or drug abuse~* Patients with severe neuropsychiatric disorders~* Non-fluency in German language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- desflurane (Type: EXPERIMENTAL): Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
- sevoflurane (Type: ACTIVE_COMPARATOR): Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application
- propofol (Type: ACTIVE_COMPARATOR): Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Trial for Psychogenic Nonepileptic Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Video electroencephalogram (EEG) confirmed diagnosis of NES~* Have at least one nonepileptic seizure per month~* Able to complete self report symptom scales~* Not receiving optimized sertraline~Exclusion Criteria:~* Equivocal EEG findings~* using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan~* allergy/sensitivity to sertraline~* current alcohol/drug dependence~* serious medical illness requiring current hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- sertraline (Type: ACTIVE_COMPARATOR): flexible dose sertraline
- CBT-ip (Type: ACTIVE_COMPARATOR): cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
- Combined (sertraline + CBT-ip) (Type: ACTIVE_COMPARATOR): flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
- Standard care (Type: ACTIVE_COMPARATOR): community care / treatment as usual: routine follow up with existing providers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ≥65 years of age at the time of consent~* Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease~* Adults who have no history of ever receiving a pneumococcal vaccine, or have a history of receiving a licensed pneumococcal vaccination ≥6 months prior to first study vaccination.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation.~* Vaccination with any influenza or pneumococcal vaccine \<6 months before investigational product administration, or planned receipt of any licensed or investigational non-study influenza vaccine during study participation.~  -- Serious chronic disorder, that in the investigator's opinion would make the participant inappropriate for entry into the study~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Coadministration Group (Type: ACTIVE_COMPARATOR): Participants receive injections of pneumococcal vaccine (20vPnC) and influenza vaccine at the same visit, and then receive an injection of saline 1 month later.
- Separate Administration Group (Type: ACTIVE_COMPARATOR): Participants receive injections of saline and influenza vaccine at the same visit, and then receive an injection of 20vPnC 1 month later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Body mass index (BMI) in the range 23-45~Exclusion Criteria:~* Diagnosis of diabetes~* Serious cardiovascular events within the past 6 months~* Use of insulin or any oral antidiabetic agent~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development & Testing of a Decision Aid for LVAD Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVAD Candidates (NYHA Class III and IV patients with an acceptable surgical risk/benefit ratio for LVAD implantation and with good psychosocial support, coping mechanisms, and financial resources, as determined by clearance from the transplant social worker)~* LVAD Patients~* LVAD Decliners~* LVAD Caregivers~Exclusion Criteria:~* subjects who lack the capacity to give informed consent

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- LVAD Decision Aid (Type: ACTIVE_COMPARATOR): Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
- No LVAD Decision Aid (Type: NO_INTERVENTION): The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete